Ultracol Program

No.

The current manufacturer information identifies the product material as PDO (polydioxanone) microspheres.

Ask the clinic to show the exact variant and local product documentation because similar-sounding injectable names are not interchangeable.

The currently verified public manufacturer page does not provide a complete side-by-side instructions-for-use comparison.

Do not infer that the variants are interchangeable from a product name or online image.

Confirm the sealed variant, local label, intended area, amount and current instructions for use before deciding.

A 2024 study of 31 adults with nasolabial folds used two ULTRACOL100 applications four weeks apart.

That small, short study protocol is not a universal schedule for every variant, area or person.

The session plan should follow assessment, the exact product documentation and review of response.

The 2024 ULTRACOL100 study assessed participants four weeks after each application and followed the two-session protocol for eight weeks.

It therefore does not establish a universal long-term duration.

Agree on a review point and avoid treating an old promotional duration as a guarantee.

The manufacturer’s current public English page states a Korea MFDS-approved indication for temporary improvement of bilateral nasolabial folds.

The verified source set used for this page does not establish an under-eye indication.

Under-eye concerns, previous procedures and alternatives need a separate physician assessment.

In the 31-person ULTRACOL100 study, no participant withdrew early because of a treatment-related adverse effect during the short follow-up.

The authors also identified the small sample and short follow-up as limitations and called for larger and longer safety evaluation.

This is not proof that uncommon or long-term complications cannot occur.

Share prior procedures in the area, medicines and supplements, allergies, health conditions, pregnancy or breastfeeding, future surgery plans and any important travel or event date.

The verified evidence does not support one universal sequence with filler or other injectables; the comparison must be individualized.

Use a current itemised quotation that names the exact product and variant, vial or quantity basis, area, physician fee, comfort plan, aftercare and follow-up.

A headline price cannot be compared fairly when the product, amount or plan differs.